Previous 10 | Next 10 |
Accomplished CMO Brings Deep Clinical Drug Development Expertise from Leading Biotech and Pharma Companies Deciphera Pharmaceuticals, Inc . (Nasdaq:DCPH), a clinical-stage biopharmaceutical company addressing key mechanisms of tumor drug resistance, today announced that it has appoint...
Deciphera Pharmaceuticals, Inc . (Nasdaq:DCPH), a clinical-stage biopharmaceutical company addressing key mechanisms of tumor drug resistance, today announced the late-breaking presentation of results from the INVICTUS pivotal Phase 3 clinical study of ripretinib in patients with advanced ga...
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that Steve Hoerter, President and Chief Executive Officer, will present at the 2019 Cantor Global Healthcare Conference on W...
Noteworthy events during the week of September 22 - 28 for healthcare investors. More news on: UroGen Pharma Ltd., Medtronic plc, ENDRA Life Sciences Inc., Healthcare stocks news, , Read more ...
Deciphera Pharmaceuticals, Inc. (Nasdaq:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that data from the Company’s INVICTUS pivotal Phase 3 study of ripretinib in patients with fourth-line and fourth-lin...
Deciphera Pharmaceuticals, Inc. (Nasdaq:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that the underwriters of its previously announced public offering of common stock have exercised their option to purchase an...
Deciphera Pharmaceuticals ( DCPH ) announced that it had achieved positive results in a phase 3 study , using its drug ripretinib to treat patients with fourth-line and fifth-line plus gastrointestinal stromal tumors ((GIST)). With these latest results, the biotech holds the potential to ...
Shares of Deciphera Pharmaceuticals (DCPH) have risen by just 1% since my September 2018 article suggested initiating a pilot position in the near term and accumulating weakness. To be fair, I had thought ESMO data for DCC-2618 would boost shares and instead they lost nearly half their value...
Deciphera Pharmaceuticals, Inc. (Nasdaq:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced the closing of its previously announced registered underwritten public offering. 10,810,810 shares of the Company’s c...
On Wednesday evening, Deciphera Pharmaceuticals, Inc. ( DCPH ) announced a $400 million capital raise consisting of 10,810,810 shares priced at $37.00 with an underwriter option for an additional $60 million worth of shares. This was double the initial proposed offering of $200 million. I ...
News, Short Squeeze, Breakout and More Instantly...
Deciphera Pharmaceuticals Inc. Company Name:
DCPH Stock Symbol:
NASDAQ Market:
Deciphera Pharmaceuticals Inc. Website:
– MOTION Phase 3 Data Demonstrate Robust Efficacy, Clinically Meaningful Improvements in Quality-of-Life Measures, and Well-Tolerated Safety Profile, Positioning Vimseltinib as Potential New TGCT Treatment – – Company Expects to Submit a New Drug Application (NDA) in ...
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...